

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-0141US1	Application No. 10/530,696
	Applicant Shuji Ozaki et al.		
	Filing Date October 28, 2005	Group Art Unit 1643	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2002/0197706	12/26/2002	Snodgrass et al.			
	2	2003/0082612	05/01/2003	Nadkarni et al.			
	3	2005/0130224	06/16/2005	Saito et al.			
	4	2007/0003556	01/07/2007	Tsuchiya et al.			
	5	2007/0281327	12/06/2007	Nakano et al.			
	6	2008/0009038	01/10/2008	Ohtomo et al.			
	7	2008/0206229	08/28/2008	Ono et al.			
	8	2008/0274110	11/06/2008	Ozaki et al.			
	9	2009/0022687	01/22/2009	Matsumoto et al.			
	10	6,699,686	03/02/2004	Brocard et al.			
	11	7,262,278	08/28/2007	Tawara et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	12	AU 755822	03/16/1999	Australia				
	13	EP 1 327 680 A1	07/16/2003	EPO				
	14	EP 1369431 A1	12/10/2003	EPO				
	15	EP 1757686	02/28/2007	EPO				
	16	JP11-500916	01/26/1999	Japan			Abstract only	
	17	JP 2004-0866862	03/18/2004	Japan			Abstract only	
	18	MX 9905856 A	07/31/2000	Mexico				
	19	WO 96/26648	09/06/1996	WIPO				
	20	WO 99/03495	01/28/1999	WIPO				
	21	WO 02/078612	10/10/2002	WIPO				
	22	WO 03/107218	12/24/2003	WIPO			Abstract only	
	23	WO 05/056602	06/23/2005	WIPO			Abstract only	
	24	WO 05/056603	06/23/2005	WIPO			Abstract only	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-0141US1	Application No. 10/530,696
	Applicant Shuji Ozaki et al.		
	Filing Date October 28, 2005	Group Art Unit 1643	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	25	WO 05/056604	06/23/2005	WIPO			Abstract only	
	26	WO 05/056605	06/23/2005	WIPO			Abstract only	
	27	WO 05/056798	06/23/2005	WIPO			Abstract only	
	28	WO 05/100560	10/27/2005	WIPO			Abstract only	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	29	Abe et al., "Surrogate thrombopoietin," <i>Immunology Letters</i> , 61:73-78 (1998)
	30	Boger et al., "Cytokine receptor dimerization and activation: prospects for small molecule agonists," <i>Bioorganic and Medicinal Chemistry</i> , 9(3):557-562 (2001)
	31	Burrone et al., "Stimulation of HLA-A,B,C by IFN-alpha. The derivation of Molt 4 variants and the differential expression of HLA-A,B,C subsets," <i>The EMBO Journal</i> , 4(11):2855-2860 (1985)
	32	Cangemi et al., "IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome," <i>International Immunology</i> , 15(12):1415-1421 (2005)
	33	CAPLUS Accession Number 2005:547624, 2 pages (2008)
	34	Caron et al., "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> , 176:1191-1195 (1992)
	35	DeJonge et al., "In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-DC3 x anti-idiotypic) induces long term survival of the murine BCL1 lymphoma model," <i>J. Immunol.</i> , 161(3):1454-1461 (1998)
	36	Kong et al., "A Single Residue, Aspartic Acid 95, in the $\delta$ Opioid Receptor Specifies Selective High Affinity Agonist Binding," <i>The Journal of Biological Chemistry</i> , 268(31):23056-23058 (1993)
	37	Kriangkum et al., "Bispecific and bifunctional single chain recombinant antibodies," <i>Biomol. Eng.</i> , 18(2):31-40 (2001)
	38	Kumar et al., "The second PDZ domain of INAD is a type I domain involved in binding to eye protein kinase C. Mutational analysis and naturally occurring variants," <i>J. Biol. Chem.</i> , 276(27):24971-2497 (2001)
	39	Mack et al., "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity," <i>Proc. Natl. Acad. Sci. USA</i> , 92(15):7021-7025 (1995)
	40	Mallender et al., "Construction, expression and activity of a bivalent bispecific single-chain antibody," <i>J. Biol. Chem.</i> , 269(1):199-206 (1994)
	41	McInnes and Schett, "Cytokines in the pathogenesis of rheumatoid arthritis," <i>Nature Reviews/Immunology</i> , 7:429-442 (2007)
	42	Medline Plus Drug Information: Dexamethasone Oral. Retrieved from the Internet: <a href="http://www.nlm.nih.gov/medlineplus/druginfo/meddmaster/a682792.html">www.nlm.nih.gov/medlineplus/druginfo/meddmaster/a682792.html</a> , retrieved 19 July 2007; last revised 04/01/2003 (see page 3) (4 pages).
	43	Milligan, "G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology," <i>Mol. Pharm.</i> , 66:1-7 (2004)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-0141US1	Application No. 10/530,696
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Shuji Ozaki et al.	
		Filing Date October 28, 2005	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	44	Palacios et al., "IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo," <i>Cell</i> , 41:272-734 (1985)
	45	Sal-man et al., "Arginine mutations within a transmembrane domain of Tar, an Escherichia coli aspartate receptor, can drive monodimer dissociation and heterodimer association in vivo," <i>Biochem. J.</i> , 385(1):29-36 (2005)
	46	Scott, "The Problem with Potency," <i>Nature Biotechnology</i> , 23(9):1037-1039 (2005)
	47	Seikimoto et al., "A Single-Chain Fv Diabody Against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment," <i>Cancer Res.</i> , 67(3):1184-1192 (2007)
	48	Sekimoto et al., "Eradication of Human Myeloma Cells by a Recombinant HLA Class I-Specific Single Chain Fv Diabody," <i>Blood</i> , 102:932a, XP009106629 (Abstract #3469) (November 2003) [Abstract of the American Society of Hematology 45 <sup>th</sup> Annual Meeting, December 6-9, 2003, San Diego, California]
	49	Sekimoto et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in Human Lymphoid Malignancies," <i>Blood</i> , 102:933a, XP002987122 (Abstract #3474) (November 2003) [Abstract of the American Society of Hematology 45th Annual Meeting, December 6-9, 2003, San Diego, California]
	50	Souyri et al., "A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors," <i>Cell</i> , 63:1137-1147 (1990)
	51	Stein et al., "Characterization of humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab," <i>Blood</i> , 108(8):2736-2744 (2006)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	